Since the notification of a novel reassortant influenza A(H7N9) virus on 31 March 2013, 1 548 laboratory-confirmed cases of human infection with avian influenza A(H7N9) virus have been reported.
The objective of this report is to systematically review data on the diagnosis, treatment, care and prevention of tuberculosis in prison settings, with a focus on the countries of the European Union and the European Economic Area.
The production of this rapid risk assessment was triggered by a report by the Czech Republic of two travelassociated cases of cholera from Zanzibar (Tanzania) and the cholera epidemics in the Horn of Africa and the Gulf of Aden.
This risk assessment contains updated advice to travellers and health professionals and the latest information on the epidemiological situation of yellow fever in Brazil.
A multi-country cluster of multidrug-resistant tuberculosis (MDR TB) involving 28 migrants has been delineated by whole genome sequencing (WGS) in migrants recently having arrived from countries in the Horn of Africa.
This second update provides information regarding the risk of EU transmission of an MDR TB clone initially detected in seven asylum seekers from the Horn of Africa who currently reside in Switzerland.
This risk assessment is triggered by the increase in the number of yellow fever cases among EU travellers with exposure in South America since August 2016 and assesses the risk of contracting yellow fever for travellers to South America.
This rapid risk assessment builds on the fifth update of the ECDC rapid risk assessments on avian influenza published on 27 January 2017 [1] and on the recent public health development dated 24 February 2017.
This rapid risk assessment reviews the ongoing outbreak of measles in Romania as well as the risk of spread and epidemiological situation of measles in EU/EEA countries.
Fifth update of the risk assessment on human infection with avian influenza A(H7N9) virus, summarising the epidemiological and virological information on the disease in China and Canada, and assessing the risk to public health in the EU/EEA.